Skip to content


  • by

Summary on Osteoporosis

Osteoporosis osteoporosis is condition of skeletal fragility due to progressive loss of bone mass it occurs in elderly people of both sexes but it’s most pronounced in postmenopausal woman osteoporosis is characterized by frequent bone fractures which are major cause of disability among the elderly population not instruct strategy to reduce bone loss in postmenopausal

Women include a diet adequate in calcium and vitamin d weight-bearing exercise and cessation of smoking in addition patient at risk for osteoporosis should avoid drugs that increase bone loss suggest glucocorticoids these phosphonates are before agent for prevention of postmenopausal osteoporosis and they have the suffix of a drone 8 as you can see there at teatro

Nate recede rotate alendronate i d’antoni pamidronate tillu tony and zoledronic acid comprising important to a group used to treat the disorder of bone remodeling such as osteoporosis and paget’s disease as well as for treatment of bone metastasis and hypercalcemia of a malignancy the bisphosphonates decreased osteo plastic bone resorption via several mechanism

Including one decrease in osteoclast ‘ok formation or activation increase in osteoclast ‘ok apoptosis a program cell death and inhibition of cholesterol biosynthesis pathway important for osteoblastic function here’s a table just summarize in terms of the potency of the class of drug that we call bits phosphonate as you can see a t28 which is the lowest internal

Potency and zoledronic acid and ibandronate the highest in terms of the importance in tell aunty resort if activity recently is also available in a once-monthly oral dosage form as is ibandronate so actor nail and boniva available in oral dosage once per month this faux fur name should be administered with at least six to eight ounces of plain water at least 30

Minutes before eating breakfast or taking other medications for patients unable to tolerate all of bisphosphonates intravenous ibandronate zoledronic acid alternative treatment for osteoporosis intravenous ibandronate is administered once every three months and zoledronic acid is a minstrel once per year alendronate residual rain and ibandronate associated with

Also vaginas and oesophageal also to minimize the risk of esophageal irritations patient should remain upright for at least 30 minutes after taking bisphosphonates selective estrogen receptor modulator some estrogen progesterone therapy is no longer the therapy of choice for treatment of osteoporosis in menopausal women because of the increased risk of breast

Cancer stroke venous thromboembolism and coronary disease raloxifene is a selective estrogen receptor modulator approved for the prevention and treatment of osteoporosis it increases bone density without increasing the risk of in the material cancer in addition raloxifene reduces the risk of invasive breast cancer in women at high risk raloxifene is the first line

Alternative from postmenopausal osteoporosis osteoporosis in women who are intolerant to bisphosphonates raloxifene reduces serum total total and low-density lipoprotein cholesterol concentration salman calcitonin a minstrel intranasally is effective and well-tolerated in the treatment of postmenopausal osteoporosis this drug reduces bone resorption but it is less

Effective than the bisphosphonates teriparatide is a recombinant segment of human parathyroid hormone that is a those subcutaneously for the treatment of osteoporosis prothero hormone given continuously lead to the solution of bone however when it is given subcutaneously once daily born formation is the predominant effect by differentially stimulating osteoblastic

Activity over osteoclast activity to be part i’d are known as for do should be a resolver patient at high risk of fractures and those who cannot tolerate other osteoporosis therapy

Transcribed from video
Osteoporosis-OPT541 By Fod Bod